Sheaff Brock Investment Advisors LLC Buys 150 Shares of Novo Nordisk A/S (NYSE:NVO)

Sheaff Brock Investment Advisors LLC boosted its stake in Novo Nordisk A/S (NYSE:NVO) by 4.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,470 shares of the company’s stock after purchasing an additional 150 shares during the quarter. Sheaff Brock Investment Advisors LLC’s holdings in Novo Nordisk A/S were worth $413,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. 1620 Investment Advisors Inc. bought a new stake in Novo Nordisk A/S in the second quarter valued at about $25,000. Strategic Investment Solutions Inc. IL bought a new stake in Novo Nordisk A/S in the second quarter valued at about $25,000. Orion Capital Management LLC bought a new stake in Novo Nordisk A/S in the first quarter valued at about $26,000. Gilliland Jeter Wealth Management LLC increased its holdings in Novo Nordisk A/S by 200.0% in the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after purchasing an additional 120 shares during the last quarter. Finally, Halpern Financial Inc. increased its holdings in Novo Nordisk A/S by 113.0% in the second quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock valued at $30,000 after purchasing an additional 113 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on NVO shares. BMO Capital Markets lowered their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO opened at $101.74 on Friday. The stock has a 50 day moving average price of $118.58 and a 200 day moving average price of $129.58. Novo Nordisk A/S has a 52 week low of $94.73 and a 52 week high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The stock has a market capitalization of $456.56 billion, a PE ratio of 32.93, a price-to-earnings-growth ratio of 1.31 and a beta of 0.42.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.